Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3746 participants.
Also called NCT03234114
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,746 participants
- Registry
-
NCT03234114
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03234114. Randomized; no masking; primary purpose treatment. Start 2018-02-03 (actual); primary completion 2024-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
- Condition
- Acute Coronary Syndrome (ACS)
- Condition
- Non-valvular Atrial Fibrillation (NVAF)
- Intervention (Drug)
- Triple antithrombotic therapy
- Intervention (Drug)
- Dual antithrombotc therapy-1
- Intervention (Drug)
- Dual antithrombotc therapy-2
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
Record details
- Record id
cardio:ct-nct03234114- Content hash
dca39f095029e7752c52323cf76d18ba909806bc607681c9f6246e8330c50154